Coeptis Therapeutics Reports Revenue Growth and Increased Losses in Q3 2025

Coeptis Therapeutics Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a significant increase in revenue and notable changes in its financial position compared to the previous fiscal period. The company generated $237,441 in revenue for the three months ended September 30, 2025, a substantial increase from zero revenue in the same period last year. For the nine months ended September 30, 2025, total revenue reached $500,996, marking a shift from a previously non-revenue-generating status. The revenue primarily stemmed from the company's NexGenAI Affiliates Network platform, which offers lead generation and webinar services.

The financial performance of Coeptis also highlighted a net loss of $2,898,763 for the third quarter, compared to a loss of $1,828,914 in the same quarter of 2024. For the nine-month period, the net loss was $10,654,290, up from $7,865,647 in the prior year. The increase in losses was attributed to higher operating expenses, which rose to $2,669,314 in the third quarter from $2,141,789 a year earlier. This increase was largely driven by professional services expenses related to consulting and legal fees associated with the company's merger activities, as well as increased stock-based compensation expenses.

Coeptis has made strategic moves to enhance its operational capabilities, including the acquisition of the NexGenAI platform, which is designed to improve marketing automation and operational efficiency. The company also reported a significant increase in its cash position, with cash and cash equivalents rising to $4,908,487 as of September 30, 2025, compared to $532,885 at the end of 2024. This increase was primarily due to proceeds from a private placement offering and draws under a Standby Equity Purchase Agreement (SEPA).

Operationally, Coeptis has expanded its workforce and capabilities, with a focus on its biotechnology and technology segments. The company reported a total of 5,157,611 shares of common stock outstanding as of September 30, 2025, up from 2,116,191 shares at the end of 2024. The increase in shares is reflective of the company's efforts to raise capital and support its growth initiatives. Additionally, the company has been actively pursuing partnerships and collaborations to advance its product development pipeline, particularly in the areas of cancer therapies and advanced marketing technologies.

Looking ahead, Coeptis Therapeutics remains focused on executing its strategic initiatives, including the anticipated merger with Z Squared, which is expected to close in late 2025 or early 2026. The company aims to leverage its enhanced financial position and operational capabilities to drive growth and achieve profitability in the future. However, management has acknowledged the ongoing challenges in the market and the need for continued capital raising efforts to support its business objectives.